Abstract
Autoimmune encephalitis often causes acute psychiatric symptoms and epileptic seizures. However, it is becoming increasingly clear that depending on the target antigen both symptoms and disease severity may vary. Furthermore, the identification and characterization of antibody subtypes are highly relevant for personalizing the treatment and to prevent relapses. Here we present an atypical case of encephalitis with cerebellar and temporal dysfunction but without seizures associated with high levels of cerebrospinal fluid neuropil antibodies against a yet unknown epitope on the neuronal surface in the cerebellum, hippocampus, thalamus, and the olfactory bulb. We treated the patient successfully with corticosteroids, plasmapheresis, and rituximab.
Introduction
Autoimmune-mediated encephalitis is commonly associated with acutely emerging psychiatric symptoms and seizures refractory to antiepileptic treatment (, ). Evidence increases that, depending on the underlying immune processes and the target antigen, structures of the central nervous system beyond the limbic cortex can be affected, leading to a great spectrum of disease presentation and severity (, ).
New insights into the mechanisms underlying antibody associated encephalitis highlight the importance of early diagnosis and antibody characterization using both specialized serum/cerebrospinal fluid (CSF) panels and immunohistochemistry to initiate an effective, personalized treatment regime that addresses both the prevention of disease progression and relapses (, ). However, due to the varying clinical, imaging, and serum/CSF manifestations, the early diagnosis and the appropriate treatment still remain a great challenge.
Here we present an atypical case of encephalitis with cerebellar and temporal dysfunction but without seizures associated with high levels of CSF neuropil antibodies against a yet unknown epitope on the neuronal surface in the cerebellum, hippocampus, thalamus, and the olfactory bulb. We treated the patient successfully with corticosteroids, plasmapheresis, and rituximab.
Case Study
A 67-years old lady was admitted to our intensive care unit (ICU) after requiring intubation for respiratory failure secondary to aspiration pneumonia and decreased consciousness.
Past medical history revealed that 6 months earlier she had been admitted to her local hospital with features of delirium (disorientation, agitation, poor memory functioning) and a cerebellar syndrome with intention tremor, severe postural instability, and dysarthria.
In the local hospital, brain MRI showed a moderate temporo-parietal atrophy (medial temporal lobe atrophy score 2, Figure 1). Repeated EEGs did not reveal epileptic activity. Routine blood and CSF analysis (cell count, glucose and protein level) were normal and investigation for infectious pathogens (varicella zoster virus, herpes zoster virus, cytomegalovirus, mumps, rubella, borrelia burgdorferi, treponema pallidum) were negative. Screening for occult malignancy (CT of thorax and abdomen) showed a right ovarian enlargement, but the surgical biopsy did not reveal a neoplastic process. Suspecting an autoimmune pathogenesis, a 5-day course of intravenous high-dose prednisolone (1,250 mg per day) and a 5-day course of intravenous immunoglobulin (IVIg) (20 g IVIg per day) were applied, leading to complete remission of dysarthria and truncal ataxia and partial remission of the delirium. The patient was subsequently transferred to the rehabilitation facility, where the cerebellar symptoms and the level of consciousness deteriorated significantly. She required oropharyngeal intubation due to respiratory failure and was admitted to our ICU.
Figure 1
Upon admission, the patient showed a septic shock due to aspiration pneumonia requiring vasopressor drugs. Following antibiotic treatment (piperacilin/tacobactam and clarithromycin) the vital signs returned to the normal ranges. After sedation was stopped the patient was in a minimally conscious state. Pupillary and corneal reflexes were regular. Gag and cough reflexes were absent.
Brain MRI did not provide new findings. EEG on admission, and repeated EEGs during the stay did not display epileptic activity. The CSF work-up showed normal cell count, glucose and protein levels. Tau- and Phospho-Tau-protein level were slightly elevated while ß-Amyloid and Amyloid-ratio were decreased (Tau 622 pg/ml, Phospho-Tau 71 pg/ml, Amyloid ratio 0.05 pg/ml, Amyloid ß1-42 393 pg/ml). Identical oligoclonal bands were found in serum and CSF. Screening for common anti-neuronal and anti-neuropil antibodies was negative (VGKC, GAD65, NMDAR, GABABR, IgLON5, AMPAR2, DPPX, LGI1, CASPR2, Glycin-receptor, mGluR5, Amphiphysin, CV2/CRMP5, Ma2/Ta, Ri, Yo, Hu, Recoverin, Sox1, Titin, Zic4, DNER/Tr).
Increased Tau-protein level, decreased level of Amyloid-ratio and temporo-parietal atrophy suggested a pre-existing Alzheimer's disease. Still suspecting an autoimmune process, CSF and serum were incubated on mouse brain sections revealing strong antibody reactivity on neuropil and neuronal surface targeting a still unknown epitope in the cerebellum, thalamus, hippocampus, and the olfactory bulb (Figure 2). In the cerebellum, antibody reactivity was predominant on granular cells. Interestingly, the patient's CSF stained only a fraction of granule cells, which further underlines specificity as it is similarly known from other autoimmune encephalitides, such as NMDAR or GABAaR encephalitis.
Figure 2
The patient received intravenous high-dose prednisolone for 5 days and 10 courses of plasmapheresis. The clinical status improved significantly: She was able to follow commands and communicate and did not show psychotic symptoms. For long-term disease modifying treatment, we then introduced intravenous rituximab (500 mg). We recommended a clinical reevaluation and repeated screening for occult malignancy with CT of thorax and abdomen in a year.
Discussion
Our case illustrates that autoimmune-mediated encephalitis may present with a broad spectrum of symptoms depending on the target antigen. Our patient developed a fast progressing condition with severe memory deficits, behavioral changes, ataxia and deterioration of consciousness, but no epileptic seizures. Correspondingly, we detected highly reactive antibodies to a yet unknown epitope on neuropil and neuronal surface in the hippocampus, cerebellum, and thalamus suggesting autoimmune mediated encephalitis although CSF workups did not detect lymphocytic pleocytosis.
In contrast to antibodies targeting intraneuronal antigens, that are not pathogenic and suggest a T-cell mediated process, antibodies against neuropil and neuronal surface proteins are often pathogenic (), but cause reversible changes and limited neuronal death (). The surface binding pattern of the antibodies in our case suggests pathogenicity involving auto-reactive B-cells and antibody-secreting plasma cells, even though the undetermined epitopic target precludes final proof. Remarkably, this type of encephalitis has been demonstrated to be more responsive to immunotherapy (, , ). Hence, a detailed classification of antibody-associated encephalitides may guide the individual therapeutic management and thereby help to improve the outcome. However, unknown and rare antibodies will be missed by most currently available commercial tests, particularly if only the serum is analyzed. Hence, a comprehensive CSF and serum workup using immunohistochemistry seems warranted.
So far, no evidence-based guidelines exist for the optimal therapeutic approach to autoimmune encephalitis associated with anti-neuropil antibodies. We applied corticosteroids, IVIg and plasmapheresis and found the strongest clinical improvement after combined treatment with corticosteroids and plasmapheresis. This observation is in line with a recent review on NMDAR-encephalitis (), the most common anti-neuropil antibody associated encephalitis. In case of a relapse or delayed diagnosis, the escalation to second-line treatment with rituximab, cyclophosphamide, or both is recommended (). We applied intravenous rituximab to selectively deplete circulating CD20-B-cells (), and achieve long-term prevention to relapses. Due to its B-cell specificity rituximab has a better safety profile as compared to anti-metabolites, such as cyclophosphamide, which inhibit cell-proliferation of both B- and T-cells and have more toxic side effects such as infertility, myelosuppression, and an increased malignancy risk (, ).
Our case demonstrates that autoimmune-mediated encephalitis needs to be considered in any condition with fast progressing central nervous symptoms even if the CSF analysis does not reveal elevated cell counts or classical antibodies and brain imaging does not detect changes indicating inflammatory processes.
Statements
Ethics statement
The patient gave written consent in accordance with the Declaration of Helsinki.
Author contributions
SET, CW, MS, MB, GF, and OO provided clinical care. SET and OO planned the case report and interpreted the data. HP analyzed the CSF data. SET drafted the manuscript. SET, CW, MS, MB, GF, and OO revised the manuscript. All authors approved the final version of the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
Petit-pedrolMArmangueTPengXBatallerLCellucciTDavisRet al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol. (2014) 13:276–86. 10.1016/S1474-4422(13)70299-0
2.
Da rochaAJNunesRHMaiaACJrDo AmaralLL. Recognizing autoimmune-mediated encephalitis in the differential diagnosis of limbic disorders. Am J Neuroradiol. (2015) 36:2196–205. 10.3174/ajnr.A4408
3.
BienCGVincentABarnettMHBeckerAJBlumckeIGrausFet al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain. (2012) 135:1622–38. 10.1093/brain/aws082
4.
DemaerelPVan desselWVan paesschenWVandenbergheRVan laereKLinnJ. Autoimmune-mediated encephalitis. Neuroradiology. (2011) 53:837–51. 10.1007/s00234-010-0832-0
5.
ShinYWLeeSTParkKIJungKHJungKYLeeSKet al. Treatment strategies for autoimmune encephalitis. Ther Adv Neurol Disord. (2018) 11:1756285617722347. 10.1177/1756285617722347
6.
KelleyBPPatelSCMarinHLCorriganJJMitsiasPDGriffithB. Autoimmune encephalitis: pathophysiology and imaging review of an overlooked diagnosis. Am J Neuroradiol. (2017) 38:1070–8. 10.3174/ajnr.A5086
7.
LancasterEDalmauJ. Neuronal autoantigens–pathogenesis, associated disorders and antibody testing. Nat Rev Neurol. (2012) 8:380–90. 10.1038/nrneurol.2012.99
8.
LancasterE. The diagnosis and treatment of autoimmune encephalitis. J Clin Neurol. (2016) 12:1–13. 10.3988/jcn.2016.12.1.1
9.
AncesBMVitalianiRTaylorRALiebeskindDSVoloschinAHoughtonDJet al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain. (2005) 128:1764–77. 10.1093/brain/awh526
10.
SuppiejANosadiniMZulianiLPelizzaMFToldoIBertossiCet al. Plasma exchange in pediatric anti-NMDAR encephalitis: a systematic review. Brain Dev. (2016) 38:613–22. 10.1016/j.braindev.2016.01.009
11.
DalmauJLancasterEMartinez-HernandezERosenfeldMRBalice-GordonR. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. (2011) 10:63–74. 10.1016/S1474-4422(10)70253-2
12.
DalakasMC. Invited article: inhibition of B cell functions: implications for neurology. Neurology. (2008) 70:2252–60. 10.1212/01.wnl.0000313840.27060.bf
13.
WisemanAC. Immunosuppressive medications. Clin J Am Soc Nephrol. (2016) 11:332–43. 10.2215/CJN.08570814
Summary
Keywords
encephalitis, cerebellitis, autoimmune, neuropil, plasmapheresis
Citation
Edwin Thanarajah S, Prüss H, Warnke C, Barbe MT, Schroeter M, Fink GR and Onur OA (2019) Atypical Autoimmune Encephalitis With Neuropil Antibodies Against a Yet Unknown Epitope. Front. Neurol. 10:175. doi: 10.3389/fneur.2019.00175
Received
15 August 2018
Accepted
11 February 2019
Published
05 March 2019
Volume
10 - 2019
Edited by
Tjalf Ziemssen, Zentrum für Klinische Neurowissenschaften (ZKN), Germany
Reviewed by
Sonja Hochmeister, Medical University of Graz, Austria; Daniel M. Altmann, Imperial College London, United Kingdom; Clara Ballerini, Università degli Studi di Firenze, Italy
Updates
Copyright
© 2019 Edwin Thanarajah, Prüss, Warnke, Barbe, Schroeter, Fink and Onur.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Sharmili Edwin Thanarajah sharmili.edwin@uk-koeln.de
This article was submitted to Multiple Sclerosis and Neuroimmunology, a section of the journal Frontiers in Neurology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.